Welcome to our dedicated page for Medtronic plc SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medtronic plc filings document material events, capital structure, registered securities, governance matters, and operating and financial disclosures for a medical-device company organized in Ireland. The 8-K record identifies MDT ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, alongside current reports used for company events and financial-result communications.
The filing record also includes exchange and registration status for debt securities, including a Form 25 notice tied to removal from listing and registration of a guarantor class of senior notes. These disclosures frame Medtronic's public-company obligations around equity, debt instruments, material agreements, and regulatory or clinical developments.
Medtronic plc executive Harry Skip Kiil reported a routine tax-withholding share disposition tied to equity compensation. On the transaction date, 6,817 Ordinary Shares were withheld at $83.32 per share to cover taxes upon settlement of performance-vesting restricted stock units that vested on April 24, 2026. After this non-market transaction, he directly holds 41,416 Medtronic Ordinary Shares.
Medtronic plc Chairman and CEO Geoffrey Martha reported a routine tax-related share disposition. On settlement of performance-vesting restricted stock units that vested on April 24, 2026, 41,936 ordinary shares were withheld to cover tax obligations at $83.32 per share. After this withholding, Martha directly holds 301,163 ordinary shares, and the filing does not show any open-market buying or selling.
Medtronic plc executive Michael Marinaro reported a routine tax-related share disposition. On April 24, 2026, performance-vesting restricted stock units vested, and on June 4, 2026, 7,471 Ordinary Shares were withheld at $83.32 per share to cover associated tax obligations. After this withholding, he directly holds 63,122 Ordinary Shares.
Medtronic plc senior vice president and Chief HR Officer Walter Matthew R. reported a routine tax-related share disposition. On June 4, 2026, 2,840 Ordinary Shares at $83.32 per share were withheld to cover taxes due on performance-vesting restricted stock units that vested on April 24, 2026. Following this withholding, he directly holds 38,689 Ordinary Shares.
Medtronic plc Chief Accounting Officer Denise L. Blomquist reported a routine tax-related share disposition. On April 24, 2026, performance-vesting restricted stock units vested, and 237 ordinary shares were withheld to cover taxes at a value of $83.32 per share. After this withholding, she directly holds 14,737 ordinary shares of Medtronic, indicating a small adjustment to her equity position tied to compensation rather than an open-market sale.
Medtronic plc reported strong Q4 and fiscal 2026 results with its fastest annual revenue growth in 10 years. Q4 revenue reached $9.807 billion, up 9.9% as reported and 6.6% organic, with GAAP EPS of $0.96 and non-GAAP EPS of $1.55, both ahead of guidance.
For FY26, revenue was $36.364 billion, up 8.4% reported and 5.8% organic. GAAP EPS was $3.73, up 3.3%, while non-GAAP EPS was $5.53, up 0.7%, as operating margin was flat on a GAAP basis and modestly lower on a non-GAAP basis.
Cardiovascular revenue grew 12.0% for the year, Neuroscience 4.5%, Medical Surgical 4.9%, and Diabetes 12.9% reported. Free cash flow was $5.426 billion, and the quarterly dividend was raised to $0.72 per share, marking the 49th consecutive annual dividend increase.
Looking to FY27, Medtronic guides to 6.75% to 7.25% organic revenue growth and diluted non-GAAP EPS of $5.90 to $6.00, implying 6.7% to 8.5% EPS growth, including the impact of a 53rd week and full-year Diabetes business consolidation.
Medtronic plc senior officer Walter Matthew R., SVP and Chief HR Officer, increased his direct equity stake through performance-based awards. On May 26, 2026, he acquired 9,149 ordinary shares via the exercise or settlement of awards and held 41,529 ordinary shares afterward.
The filing also shows the exercise of 8,449 Performance Share Units, each representing a contingent right to one Medtronic share. These units were originally granted on July 31, 2023, vested on April 24, 2026, and were settled based on performance certified on May 26, 2026. No open-market purchases or sales were reported; this reflects compensation vesting rather than trading.
Medtronic plc executive Brett A. Wall, EVP & President of Neuroscience, exercised performance-based share units that were granted on July 31, 2023. This settlement delivered 24,214 ordinary shares after performance was certified on May 26, 2026, following vesting on April 24, 2026.
After these transactions, Wall directly holds 82,183 Medtronic ordinary shares, which the disclosure notes include 527 shares acquired through dividend reinvestment since his prior report. The activity reflects compensation-related equity vesting rather than an open-market purchase or sale.
Medtronic plc Chairman and CEO Geoffrey Martha reported a compensation-related equity transaction involving performance share units. On May 26, 2026, he exercised performance-vesting share units into 85,461 Ordinary Shares, with the performance share units having fully vested on April 24, 2026. A related entry shows 94,963 Ordinary Shares credited, and his direct holdings after these transactions total 343,099 Ordinary Shares, which include 1,743 shares acquired through dividend reinvestment since his last report. Each performance share unit represented a contingent right to receive one Medtronic ordinary share, granted on July 31, 2023 and settled based on performance certified on May 26, 2026. The filing does not report any open‑market purchases or sales, only the exercise and settlement of equity awards.